HUE045163T2 - Új ellenanyagok foszforilkolin ellen - Google Patents

Új ellenanyagok foszforilkolin ellen

Info

Publication number: HUE045163T2
Authority: HU; Hungary
Prior art keywords: antibodies against; new antibodies; against phosphorylcholine; phosphorylcholine; new
Prior art date: 2011-08-09

Application number

HUE12747915A

Other languages

English (en)

Inventor

Knut Pettersson

Ola Camber

Dan Sexton

Andrew E Nixon

Original Assignee

Athera Biotechnologies Ab

Dyax Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-08-09

Filing date

2012-08-08

Publication date

2019-12-30

2012-08-08 Application filed by Athera Biotechnologies Ab, Dyax Corp filed Critical Athera Biotechnologies Ab

2019-12-30 Publication of HUE045163T2 publication Critical patent/HUE045163T2/hu

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Diabetes (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Vascular Medicine (AREA)
Microbiology (AREA)
Transplantation (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Reproductive Health (AREA)
Mycology (AREA)
Epidemiology (AREA)

HUE12747915A 2011-08-09 2012-08-08 Új ellenanyagok foszforilkolin ellen HUE045163T2 (hu)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201161521593P	2011-08-09	2011-08-09

Publications (1)

Publication Number	Publication Date
HUE045163T2 true HUE045163T2 (hu)	2019-12-30

Family

ID=46679261

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HUE12747915A HUE045163T2 (hu)	2011-08-09	2012-08-08	Új ellenanyagok foszforilkolin ellen

Country Status (27)

Country	Link
US (3)	US9803028B2 (hu)
EP (1)	EP2742068B1 (hu)
JP (1)	JP6277125B2 (hu)
KR (1)	KR101947758B1 (hu)
CN (1)	CN104039832B (hu)
AR (1)	AR087485A1 (hu)
AU (1)	AU2012293646B2 (hu)
BR (1)	BR112014002929A8 (hu)
CA (1)	CA2843921A1 (hu)
CY (1)	CY1121950T1 (hu)
DK (1)	DK2742068T3 (hu)
ES (1)	ES2732838T3 (hu)
HK (1)	HK1200852A1 (hu)
HR (1)	HRP20190988T1 (hu)
HU (1)	HUE045163T2 (hu)
LT (1)	LT2742068T (hu)
MX (1)	MX364425B (hu)
PL (1)	PL2742068T3 (hu)
PT (1)	PT2742068T (hu)
RS (1)	RS58986B1 (hu)
RU (1)	RU2654584C2 (hu)
SG (1)	SG2014009344A (hu)
SI (1)	SI2742068T1 (hu)
TR (1)	TR201909072T4 (hu)
TW (1)	TWI707873B (hu)
WO (1)	WO2013020995A1 (hu)
ZA (1)	ZA201400665B (hu)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2843960C (en)	2011-08-09	2020-09-15	Athera Biotechnologies Ab	Antibodies binding to phosphorylcholine (pc) and/or pc conjugates
PL2742068T3 (pl) *	2011-08-09	2020-01-31	Athera Biotechnologies Ab	Nowe przeciwciała przeciwko fosforylcholinie
US10942184B2 (en)	2012-10-23	2021-03-09	Caris Science, Inc.	Aptamers and uses thereof
CA2979361A1 (en)	2015-03-09	2016-09-15	Caris Science, Inc.	Method of preparing oligonucleotide libraries
EP3314027A4 (en)	2015-06-29	2019-07-03	Caris Science, Inc.	THERAPEUTIC OLIGONUCLEOTIDES
AU2016298317B2 (en)	2015-07-28	2021-02-18	Caris Science, Inc.	Targeted oligonucleotides

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2402664A1 (fr)	1977-09-07	1979-04-06	Agronomique Inst Nat Rech	Produits de couplage phosphorylcholine, composes amines procede d'obtention et applications
US5955584A (en)	1986-03-31	1999-09-21	Charter Ventures	Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof
ES2070820T3 (es)	1986-08-06	1995-06-16	Scripps Clinic Res	Anticuerpos monoclonales especificos de la apolipoproteina b, producidos por dos nuevos hibridomas.
JPH02188532A (ja)	1989-01-17	1990-07-24	Otsuka Pharmaceut Co Ltd	リポソームワクチン
WO1990012632A1 (en)	1989-04-19	1990-11-01	The United States Of America, Represented By The Secretary, United States Department Of Commerce	Process for removing c-reactive protein and anti-phosphorylcholine antibodies from biological fluids
JP3283041B2 (ja)	1990-07-13	2002-05-20	学校法人藤田学園	人工抗体
WO1992010203A1 (en)	1990-12-10	1992-06-25	Alving Carl R	A vaccine against cholesterol to prevent hypercholesterolemia and atherosclerosis
RU2014609C1 (ru) *	1991-06-06	1994-06-15	Московский институт тонкой химической технологии им.М.В.Ломоносова	Способ определения белков, специфичных к фосфорилхолину
CA2131150A1 (en)	1992-03-03	1993-09-16	Michel C. Nussenzweig	Receptor complexes with b29 (ig-beta or ig-gamma) and their uses
AU5959494A (en)	1992-12-29	1994-07-19	Entremed, Inc	Vaccines against sterols
DE69411154T2 (de)	1993-02-22	1998-10-22	Alza Corp., Palo Alto, Calif.	Mittel zur oralen gabe von wirkstoffen
US5455032A (en)	1993-07-29	1995-10-03	The United States Of America As Represented By The Department Of Health And Human Services	Use of phosphocholine hapten conjugates in vaccines
US6375925B1 (en)	1996-11-08	2002-04-23	The Regents Of The University Of California	Methods and reagents for non-invasive imaging of atherosclerotic plaque
AU1159497A (en)	1996-11-08	1998-06-03	Regents Of The University Of California, The	Methods and reagents for non-invasive imaging of atherosclerotic plaque
US6225070B1 (en)	1997-08-07	2001-05-01	The Regents Of The University Of California	Antibodies to oxidation-specific epitopes on lipoprotein and methods for their use in detecting, monitoring and inhibiting the growth of atheroma
US20040185039A1 (en)	2002-08-30	2004-09-23	Heinz Kohler	Therapeutic applications of noncovalent dimerizing antibodies
US6300308B1 (en)	1997-12-31	2001-10-09	Board Of Regents, The University Of Texas System	Methods and compositions for inducing autoimmunity in the treatment of cancers
SE9802402D0 (sv)	1998-07-03	1998-07-03	Karolinska Innovations Ab	Method of diagnosing cardiovascular disease and early atherosclerosis
DK1095271T3 (da)	1998-07-03	2003-12-15	Athera Biotechnologies Ab	Fremgangsmåde til diagnose af hjertekar-sygdomme og tidlig aterosklerose
CA2389849A1 (en)	1999-10-26	2001-05-10	Regents Of The University Of California	Reagents and methods for diagnosing, imaging and treating atherosclerotic disease
SE0000855D0 (sv)	2000-03-15	2000-03-15	Karolinska Innovations Ab	Antigenic composition useful as a vaccine against atherosclerosis
AU2001259730A1 (en)	2000-05-12	2001-11-26	The Regents Of The University Of California	Standardized oxidized ldl assay
DE10041515A1 (de)	2000-08-24	2002-03-14	Gerold Schuler	Verfahren zur Herstellung gebrauchsfertiger, Antigen-beladener oder -unbeladener, kryokonservierter reifer dendritischer Zellen
US6838452B2 (en)	2000-11-24	2005-01-04	Vascular Biogenics Ltd.	Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
SE0103754L (sv)	2001-04-05	2002-10-06	Forskarpatent I Syd Ab	Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
WO2004091520A2 (en)	2003-04-11	2004-10-28	The Regents Of The University Of California	Methods and compositions for treating atherosclerosis
AU2005233361B2 (en)	2004-04-15	2011-02-24	Athera Biotechnologies Ab	Phosphorylcholine conjugates and corresponding antibodies
CA2575791A1 (en)	2004-08-03	2006-02-16	Dyax Corp.	Hk1-binding proteins
EP1868651A4 (en)	2005-04-12	2010-10-06	Univ Duke	METHOD FOR INDUCING ANTIBODIES THAT NEUTRALIZE THE HUMAN IMMUNODEFICIENCY VIRUS
AU2006330807A1 (en)	2005-11-28	2007-07-05	Medimmune, Llc	Antagonists of HMBG1 and/or rage and methods of use thereof
WO2008150485A2 (en)	2007-05-29	2008-12-11	Wyeth	Erbb2 binding proteins and use thereof
JP5122908B2 (ja)	2007-10-17	2013-01-16	日泉化学株式会社	自動車の内装用部材の取り付け構造
WO2010003602A1 (en)	2008-07-07	2010-01-14	Athera Biotechnologies Ab	New therapeutic and diagnostic methods for alzheimer's disease
WO2012010291A1 (en)	2010-07-21	2012-01-26	Athera Biotechnologies Ab	Diagnostic and therapeutic methods and compositions for metabolic disease
KR102502293B1 (ko)	2011-01-06	2023-02-21	다케다 파머수티컬 컴패니 리미티드	혈장 칼리크레인 결합 단백질
CA2843960C (en)	2011-08-09	2020-09-15	Athera Biotechnologies Ab	Antibodies binding to phosphorylcholine (pc) and/or pc conjugates
PL2742068T3 (pl) *	2011-08-09	2020-01-31	Athera Biotechnologies Ab	Nowe przeciwciała przeciwko fosforylcholinie

2012
- 2012-08-08 PL PL12747915T patent/PL2742068T3/pl unknown
- 2012-08-08 TR TR2019/09072T patent/TR201909072T4/tr unknown
- 2012-08-08 SG SG2014009344A patent/SG2014009344A/en unknown
- 2012-08-08 WO PCT/EP2012/065505 patent/WO2013020995A1/en active Application Filing
- 2012-08-08 CN CN201280049552.0A patent/CN104039832B/zh not_active Expired - Fee Related
- 2012-08-08 TW TW101128575A patent/TWI707873B/zh not_active IP Right Cessation
- 2012-08-08 KR KR1020147006274A patent/KR101947758B1/ko active IP Right Grant
- 2012-08-08 LT LTEP12747915.2T patent/LT2742068T/lt unknown
- 2012-08-08 MX MX2014001313A patent/MX364425B/es active IP Right Grant
- 2012-08-08 CA CA2843921A patent/CA2843921A1/en not_active Abandoned
- 2012-08-08 SI SI201231604T patent/SI2742068T1/sl unknown
- 2012-08-08 JP JP2014524371A patent/JP6277125B2/ja not_active Expired - Fee Related
- 2012-08-08 DK DK12747915.2T patent/DK2742068T3/da active
- 2012-08-08 HU HUE12747915A patent/HUE045163T2/hu unknown
- 2012-08-08 EP EP12747915.2A patent/EP2742068B1/en active Active
- 2012-08-08 RU RU2014108815A patent/RU2654584C2/ru active
- 2012-08-08 US US14/237,035 patent/US9803028B2/en active Active
- 2012-08-08 AU AU2012293646A patent/AU2012293646B2/en not_active Ceased
- 2012-08-08 ES ES12747915T patent/ES2732838T3/es active Active
- 2012-08-08 RS RS20190807A patent/RS58986B1/sr unknown
- 2012-08-08 AR ARP120102895A patent/AR087485A1/es unknown
- 2012-08-08 BR BR112014002929A patent/BR112014002929A8/pt not_active Application Discontinuation
- 2012-08-08 PT PT12747915T patent/PT2742068T/pt unknown
2014
- 2014-01-28 ZA ZA2014/00665A patent/ZA201400665B/en unknown
2015
- 2015-02-05 HK HK15101305.1A patent/HK1200852A1/xx unknown
2017
- 2017-09-28 US US15/719,520 patent/US20180086848A1/en not_active Abandoned
2019
- 2019-05-30 HR HRP20190988TT patent/HRP20190988T1/hr unknown
- 2019-06-28 CY CY20191100683T patent/CY1121950T1/el unknown
2021
- 2021-04-13 US US17/229,837 patent/US20210238311A1/en not_active Abandoned

Also Published As

Publication number	Publication date
BR112014002929A8 (pt)	2021-09-28
MX364425B (es)	2019-04-25
US20210238311A1 (en)	2021-08-05
US20180086848A1 (en)	2018-03-29
CN104039832B (zh)	2021-02-12
DK2742068T3 (da)	2019-06-11
KR20140068948A (ko)	2014-06-09
AU2012293646A1 (en)	2014-02-20
HRP20190988T1 (hr)	2019-09-20
ZA201400665B (en)	2019-08-28
HK1200852A1 (en)	2015-08-14
RU2654584C2 (ru)	2018-05-21
EP2742068A1 (en)	2014-06-18
US20140178410A1 (en)	2014-06-26
RS58986B1 (sr)	2019-08-30
JP2014525233A (ja)	2014-09-29
SG2014009344A (en)	2014-07-30
BR112014002929A2 (pt)	2017-03-28
MX2014001313A (es)	2014-07-28
AU2012293646A8 (en)	2014-03-06
AU2012293646B2 (en)	2017-08-31
KR101947758B1 (ko)	2019-02-14
TR201909072T4 (tr)	2019-08-21
RU2014108815A (ru)	2015-09-20
PT2742068T (pt)	2019-07-08
ES2732838T3 (es)	2019-11-26
US9803028B2 (en)	2017-10-31
AR087485A1 (es)	2014-03-26
JP6277125B2 (ja)	2018-02-07
PL2742068T3 (pl)	2020-01-31
SI2742068T1 (sl)	2019-08-30
TW201321415A (zh)	2013-06-01
EP2742068B1 (en)	2019-04-03
CN104039832A (zh)	2014-09-10
WO2013020995A1 (en)	2013-02-14
CA2843921A1 (en)	2013-02-14
TWI707873B (zh)	2020-10-21
CY1121950T1 (el)	2020-10-14
LT2742068T (lt)	2019-07-10

Publication	Publication Date	Title
HUS2300021I1 (hu)	2023-07-28	Anti-IL-36R antitestek
HRP20180640T1 (hr)	2018-06-01	Anti-b7-h3 antitijelo
IL259826A (en)	2018-07-31	Anti-alphabetatisiar antibody
GB201103955D0 (en)	2011-04-20	Antibodies
GB201112056D0 (en)	2011-08-31	Antibodies
GB201120991D0 (en)	2012-01-18	Microsensor
TWI563004B (en)	2016-12-21	Anti-hxcr1 antibody
PT2707391T (pt)	2018-02-06	Anticorpos contra her3
HK1200852A1 (en)	2015-08-14	New antibodies against phosphorylcholine
EP2714074A4 (en)	2015-04-22	ANTIBODIES AGAINST EMR1
EP2769988A4 (en)	2015-08-05	ANTI-GAP43 ANTIBODY
EP2751750A4 (en)	2015-04-01	IDENTIFY THE USER TARGET RELATION
GB201116342D0 (en)	2011-11-02	Antigen combinations
GB201103827D0 (en)	2011-04-20	Biosensor